Lianying CT and magnetic resonance were sold to 33 county hospitals in Fujian!

Medical Network April 19th. Lian Ying made a 'big victory' in Fujian and won the configuration of Class B large-scale medical equipment in 34 hospitals.

On April 17, the Fujian Provincial Health and Family Planning Commission announced the release of the list of large-scale medical equipment allocation licenses for category B (the 42nd batch), and announced 49 companies in Fujian Province. hospital The unit is configured with a list of large equipment category B. The equipment includes CT, MRI, LA, DSA, etc.

The list shows that out of the 13 bid-winning companies, foreign companies, Philips, Siemens accounted for a relatively high; domestic companies only Shanghai Union, Besda (Shenzhen) 2. However, unlike in the past, a company in Shanghai Lian Ying won the bid in 34 hospitals. 46 sets of CT/MRI equipment, accounting for 72%, changed the situation of 'imported equipment accounted for the bulk'.

The list also showed that the orders for CT/MRI equipment of Lianying were mainly deployed in county-level hospitals. Lianying won 27 counties, 4 county-level cities, 1 municipal district, and 1 Pingtan comprehensive experimental area in Fujian Province. There are orders for a total of 33 county-level hospitals, as well as orders for the Fujian Provincial Geriatric Hospital directly under the Fujian Provincial Health and Family Planning Commission.

In the cities of Fujian Province, it is also Putian City and Xiamen City. The hospitals in these two places have no products deployed.

Recently, China medicine Materials Association released 2017medical instruments The development status report pointed out that in recent years, China’s high-end medical device industry has enterprise Efforts have been made with rapid development, and in particular imaging diagnostic equipment has gradually achieved import substitution.

However, in the field of large-scale equipment such as CT and NMR, the global market has long been monopolized by multinational corporations, and there is still a large gap between the technological level and comprehensive performance of high-end products in China compared to developed countries, and the clinical use time is short. The international market has a low degree of recognition. External exports are still in a weak position. The internationalization road is a long way to go.

Note: The approval date in the above list is April 8, 2018, all new configurations.